GeneDx Holdings Corp.

NASDAQ:WGS

Medical - Healthcare Information Services

Healthcare
$51.96 +2.69%

+$1.52 today

Market cap
$1.56B
Beta
1.97
P/E (TTM)
-21.8
EPS (TTM)
-$2.65
52W Low $32.21High $170.87

Volume 1.71M

Average 1.28M

WGS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

GeneDx Holdings Corp.NASDAQ: WGS

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $19.66M rose 32.2% year over year, behind the +64.3% change in trailing-twelve-month research & development. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.

Context

  • Research & development amounted to 16.8% of revenue in FY2025, up 1.9 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +32.2% toward the trailing-twelve-month pace of +64.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.66M-0.7% QoQ
Last fiscal yearDec 2025
$72.03M+57.5% YoY
LTMJun 2026
$83.32M+64.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.2%——
1 year+57.5%——
3-year CAGR-5.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
72.03M USD
Year-over-year change
+57.5%
4-year CAGR
-9.0%

Research & Development vs competitors

How WGS compares with its peers on the latest reported figures

  • WGS's LTM Jun 2026 research & development of $83.32M is the 2nd highest of the 9 companies compared; the peer median is $52.93M.
  • Its year-over-year change of +64.3% is the 2nd highest of 9, against a peer median of +8.2%.
  • Research & development amounts to 18.3% of revenue for WGS, versus a peer median of 15.3%.
WGS Competitors Peer median
Research & Development for WGS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
WGSGeneDx Holdings Corp.LTM Jun 2026$83.32M +64.3%-5.8%18.3%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$55.69M +11.9%+23.1%17.4%
CSTLCastle Biosciences, Inc.LTM Mar 2026$53.69M +5.8%+4.9%15.8%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.59M +68.3%+29.6%902.4%
MDXHMDxHealth S.A.FY2025$10.35M -1.9%+11.1%9.6%
Peer median (excluding WGS) $52.93M+8.2%+7.7%15.3%

Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue212.2M234.69M202.57M305.45M427.54M
Cost of Revenue228.8M261.44M112.56M111.05M129.37M
Gross Profit(16.6M)(26.75M)90.01M194.4M298.17M
Gross Margin-7.8%-11.4%44.4%63.6%69.7%
Research & Development105.16M86.2M58.27M45.72M72.03M
Selling, General & Admin318.73M338.24M194.71M168.48M239.22M
Operating Expenses429.55M640.9M270.6M217.61M311.25M
Depreciation & Amortization21.81M59.31M33.73M21.95M25.22M
EBITDA(220.75M)(398.2M)(136.46M)(27.64M)6.63M
EBITDA Margin-104.0%-169.7%-67.4%-9.1%1.5%
Operating Income(446.15M)(667.65M)(180.6M)(23.21M)(11.8M)
Operating Margin-210.3%-284.5%-89.2%-7.6%-2.8%
Interest Income79K2.54M1.11M00
Interest Expense2.84M3.21M03.03M2.54M
Other Income / Expenses200.76M69.62M3.9M(29.42M)(9.34M)
Income Before Tax(245.39M)(598.03M)(176.69M)(52.63M)(21.14M)
Pre-Tax Margin-115.6%-254.8%-87.2%-17.2%-4.9%
Income Tax Expense0(49.05M)(926K)(343K)(116K)
Net Income(245.39M)(548.98M)(175.77M)(52.29M)(21.02M)
Net Margin-115.6%-233.9%-86.8%-17.1%-4.9%
EPS (Basic)(74.93)(53.63)(7.23)(1.94)(0.73)
EPS (Diluted)(74.93)(53.63)(7.23)(1.94)(0.73)
Weighted Avg Shares3.28M10.24M24.31M26.89M26.89M
Weighted Avg Shares (Diluted)3.28M10.24M24.31M26.89M26.89M

GeneDx Holdings Corp.

NASDAQ:WGS

Intrinsic Alpha fair value

Locked

Current Price

$51.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.